

# PRIOR AUTHORIZATION CRITERIA

<b>DRUG CLASS</b>	<b>ANABOLIC STEROIDS</b>
<b>BRAND NAME (generic)</b>	<b>ANADROL-50 (oxymetholone)</b>
<b>Status: CVS Caremark Criteria</b>	
<b>Type: Initial Prior Authorization</b>	<b>Ref # 1087-A</b>

## POLICY

### FDA-APPROVED INDICATIONS

Anadrol-50 Tablets is indicated in the treatment of anemias caused by deficient red cell production. Acquired aplastic anemia, congenital aplastic anemia, myelofibrosis and the hypoplastic anemias due to the administration of myelotoxic drugs often respond. Anadrol-50 Tablets should not replace other supportive measures such as transfusion, correction of iron, folic acid, vitamin B<sub>12</sub> or pyridoxine deficiency, antibacterial therapy and the appropriate use of corticosteroids.

### Compendial Uses

Cachexia associated with AIDS (HIV wasting)<sup>3</sup>

### COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

- The requested drug is being prescribed for any of the following: A) Anemia due to deficient red cell production, (e.g., acquired aplastic anemia, congenital aplastic anemia, myelofibrosis, the hypoplastic anemias due to the administration of myelotoxic drugs, Fanconi's anemia), B) Cachexia associated with acquired immunodeficiency syndrome (AIDS) (human immunodeficiency virus [HIV] wasting)

### REFERENCES

1. Anadrol-50 [package insert]. Marietta, GA: Alaven Pharmaceuticals LLC; December 2006.
2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Hudson, OH: Wolters Kluwer Clinical Drug Information, Inc. <http://online.lexi.com/>. Accessed December 2019.
3. Micromedex (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. <http://www.micromedexsolutions.com/>. Accessed December 2019.
4. Food and Drug Administration. Testosterone and other anabolic androgenic steroids (AAS): FDA statement – risks associated with abuse and dependence. Silver Spring, MD; 2016 Oct 25. Available at: <https://wayback.archive-it.org/7993/20170111133941/http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm526151.htm>. Accessed December 2019.